|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF282 |
Gene summary for ZNF282 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF282 | Gene ID | 8427 |
| Gene name | zinc finger protein 282 | |
| Gene Alias | HUB1 | |
| Cytomap | 7q36.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q86YG2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8427 | ZNF282 | P128T-E | Human | Esophagus | ESCC | 1.85e-10 | 2.49e-01 | 0.1241 |
| 8427 | ZNF282 | P130T-E | Human | Esophagus | ESCC | 1.83e-15 | 3.23e-01 | 0.1676 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF282 | M2MAC | Breast | DCIS | VDR,CD80,NSF, etc. | 0.00e+00 |  |
| ZNF282 | MON | Breast | DCIS | VDR,CD80,NSF, etc. | 0.00e+00 | |
| ZNF282 | MAST | Breast | Precancer | VDR,CD80,NSF, etc. | 2.25e-02 |  |
| ZNF282 | CD8TEX | Breast | Precancer | VDR,CD80,NSF, etc. | 0.00e+00 | |
| ZNF282 | CD4TN | Breast | Precancer | VDR,CD80,NSF, etc. | 0.00e+00 | |
| ZNF282 | GC | Breast | Precancer | VDR,CD80,NSF, etc. | 0.00e+00 | |
| ZNF282 | pDC | Breast | Precancer | VDR,CD80,NSF, etc. | 0.00e+00 | |
| ZNF282 | TRANS | Esophagus | ESCC | CFLAR,CSGALNACT1,TPRA1, etc. | 1.01e-01 |  |
| ZNF282 | MYOFIB | Esophagus | Healthy | MIR155HG,MESP1,WASF1, etc. | 1.10e-02 |  |
| ZNF282 | AT1 | Lung | AAH | SMCR8,DGKG,ZNF551, etc. | 3.72e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF282 | SNV | Missense_Mutation | novel | c.1896C>G | p.Cys632Trp | p.C632W | Q9UDV7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ZNF282 | SNV | Missense_Mutation | c.965N>T | p.Ser322Phe | p.S322F | Q9UDV7 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF282 | SNV | Missense_Mutation | c.421N>A | p.Val141Met | p.V141M | Q9UDV7 | protein_coding | tolerated(0.33) | possibly_damaging(0.636) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
| ZNF282 | SNV | Missense_Mutation | c.1846N>G | p.Asn616Asp | p.N616D | Q9UDV7 | protein_coding | tolerated(0.39) | benign(0.015) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF282 | SNV | Missense_Mutation | rs374922258 | c.457G>A | p.Val153Met | p.V153M | Q9UDV7 | protein_coding | deleterious(0.04) | benign(0.266) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZNF282 | insertion | Nonsense_Mutation | novel | c.691_692insGATTGCAAACTGAAATCGGCTTTCTGTA | p.Tyr231Ter | p.Y231* | Q9UDV7 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| ZNF282 | insertion | Frame_Shift_Ins | novel | c.1895_1896insTGATT | p.Gly633AspfsTer59 | p.G633Dfs*59 | Q9UDV7 | protein_coding | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF282 | insertion | Frame_Shift_Ins | novel | c.492_493insATGGAGGAATGGGTGCTTTTGATGGAAACAC | p.Gln165MetfsTer70 | p.Q165Mfs*70 | Q9UDV7 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF282 | insertion | Nonsense_Mutation | novel | c.986_987insAGCTCCACAAACCTCATCCCCCCCTTAGTCA | p.Ile330AlafsTer9 | p.I330Afs*9 | Q9UDV7 | protein_coding | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| ZNF282 | insertion | Frame_Shift_Ins | novel | c.1643_1644insGCAGTTGAAGCTCTTCT | p.Cys548TrpfsTer25 | p.C548Wfs*25 | Q9UDV7 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |